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Abstract: 37 
Objectives: 38 
Following lung resection, there is a decrease in functional capacity and quality of life which is 39 
not fully explained by changes in pulmonary function. Previous work demonstrates that B-40 
type Natriuretic Peptide (BNP) is associated with short and long term complications following 41 
lung resection, leading to the suggestion that cardiac dysfunction may contribute to 42 
functional deterioration.  Our aim was to investigate any relationship between BNP and 43 
subjective and objective indices of functional deterioration following lung resection surgery. 44 
Methods: 45 
Twenty-seven patients undergoing lung resection had serum BNP measured pre-operatively, 46 
on post-operative day (POD)1, POD2, and at two months post-operatively. Functional 47 
deterioration was assessed using Six Minute Walk Tests (6MWT) and the Medical Research 48 
Council (MRC) dyspnoea scale. ‘Deterioration in functional capacity’ was defined as either 49 
an increase in MRC dyspnoea score or a significant decrease in 6MWT distance. 50 
Results: 51 
BNP increased over time (p<0.01) and was significantly elevated on POD1 and POD2 52 
(p<0.02 for both). Seventeen patients demonstrated functional deterioration 2-months post-53 
operatively. At all peri-operative timepoints, BNP was significantly higher in patients showing 54 
deterioration (p<0.05 for all). Pre-operative BNP was predictive of functional deterioration at 55 
2 months with an AUROC of 0.82 (p=0.01, CI: 0.65-0.99).  56 
Conclusions: 57 
This study has demonstrated, using subjective and objective measures, that pre-operative 58 
BNP is a predictor of functional deterioration following lung resection. BNP may have a role 59 
in pre-operative risk stratification in this population, allowing therapy in future to be targeted 60 
toward high risk patients with the aim of preventing post-operative cardiac dysfunction. 61 
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Introduction 67 
Lung cancer remains the leading cause of cancer death worldwide [1]. In suitable patients 68 
lung resection offers the best chance of cure; as a result an increasing number of surgeries 69 
are being undertaken, contributing to improved survival [2]. Although surgery has a low 70 
associated mortality, lung resection leaves patients with a high burden of both short and long 71 
term morbidity. Functional capacity plays an important role in the physical and social wellbeing 72 
of patients with lung cancer; yet unfortunately there is a well-documented decrease in quality 73 
of life, functional capacity and exercise tolerance following lung resection [3-5], with as many 74 
as 40% of patients reporting disabling dyspnoea [6]. Clinical practice guidelines advocate the 75 
use of predicted post-operative (ppo) lung function to predict the risk of post-operative 76 
dyspnoea [7-9]. This is calculated by adjusting pre-operative lung function test results to reflect 77 
the quantity of lung resected. Predicted post-operative pulmonary function has however been 78 
shown to be poorly associated with changes in exercise capacity [10] and quality of life [11] 79 
following surgery. This lack of association suggests other factors may be involved in the 80 
aetiology of post-operative functional limitation. Several authors have suggested functional 81 
impairment may result from cardiac rather than pulmonary limitation [12, 13], and we suggest 82 
that B-type Natriuretic Peptide (BNP) may have a role in identifying patients at risk of post-83 
operative functional limitation. 84 
BNP is a 32-amino acid polypeptide released from the cardiac ventricles in response to 85 
myocardial stretch and strain. It is easily measurable in plasma in either its active form or an 86 
inactive precursor – N-Terminal-pro BNP. BNP increases following lung resection, with the 87 
magnitude of increase associated with the amount of lung tissue resected [14]. In non-cardiac 88 
surgeries BNP has been shown to be predictive of both short and long term mortality [15, 16]. 89 
Furthermore, BNP has been demonstrated to identify patients at risk of both short and long 90 
term cardio-pulmonary complications of non-cardiac surgery [17-19], with higher levels of BNP 91 
predicting higher complications [15]. These findings have been validated by meta-analysis [20], 92 
and consequentially, BNP has been included in both the American Heart Association and 93 
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European Society of Anaesthesiology guidelines for assessing peri-operative cardiac risk in 94 
patients undergoing non-cardiac surgery [21, 22]. In patients undergoing thoracic surgery, 95 
elevated BNP has been associated with increased rates of atrial fibrillation and other cardiac 96 
dysrhythmias [23]. 97 
There is no previous work comparing BNP to functional capacity in patients undergoing lung 98 
resection. Given that impaired functional capacity may be related in part to cardiac function, 99 
we hypothesised there would be an association between peri-operative BNP and post-100 
operative functional limitation. 101 
Materials and Methods 102 
This study is an a-priori secondary endpoint of a larger observational study using 103 
cardiovascular magnetic resonance imaging to investigate right ventricular dysfunction 104 
following lung resection (ClinicalTrials.gov: NCT01892800).  105 
Participants 106 
Ethics approval for the study was provided by the West of Scotland Research Ethics 107 
Committee (REC Ref: 134/WS/0055) and all participants provided written informed consent. 108 
Patients attending for elective lung resection at the Golden Jubilee National Hospital (a tertiary 109 
referral hospital providing cardiothoracic surgical services for the West of Scotland) between 110 
August 2013 and September 2014 were screened and approached for inclusion. Subjects who 111 
were pregnant, participating in any investigational research which could undermine the 112 
scientific basis of the study, had contraindications to cardiovascular magnetic resonance or 113 
were undergoing; wedge / segmental / sub-lobar lung resection, pneumonectomy, isolated 114 
middle lobectomy or thoracoscopic / minimal access lung resection, were excluded. Surgical 115 
technique was standardised to a single surgeon performing a postero-lateral muscle sparing 116 
thoracotomy and lobectomy with anatomically appropriate lymph node clearance. Anaesthetic 117 
technique was standardised and included the use of a volatile agent for anaesthetic 118 
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maintenance, intra-operative lung protective ventilatory strategies and thoracic epidural 119 
blockade for post-operative analgesia. 120 
Measurements 121 
BNP 122 
Blood samples were collected into EDTA test tubes at baseline, immediately post-op, on post-123 
operative days (POD) 1 and 2, and 2 months post-op. Analysis was performed immediately at 124 
point of care using the Alere Triage® system (Alere Ltd. Stockport, UK), according to the 125 
manufacturer’s guidelines. Quality control checks were carried out on the equipment regularly 126 
to ensure accuracy in line with the manufacturer’s recommendations; the coefficient of 127 
variation for BNP measurements was 5%. Patients and clinicians were blinded to BNP results 128 
to reduce bias and to prevent BNP results altering patient management. 129 
Functional Capacity 130 
Functional capacity was assessed subjectively using the Medical Research Council (MRC) 131 
dyspnoea score, and objectively by Six Minute Walk Test (6MWT). Patients completed MRC 132 
dyspnoea scores [24] as an assessment of self-reported functional capacity at baseline, two 133 
months post-op and one year post-op. The 6MWT was carried out according to standard 134 
guidelines [25] over a 30 metre course by trained respiratory physiologists pre-operatively and 135 
2 months post-operatively. In order to assess any decrease in walk distance a ‘minimal 136 
important difference’ was defined. A decrease in walking distance of 28 metres has been 137 
validated as the minimally important difference detected by the 6MWT in a cohort of COPD 138 
patients, and, as there has been no minimally important difference defined in a lung resection 139 
cohort, this was used in our study [26]. 140 
To facilitate integration of subjective and objective assessments of functional capacity, the 141 
primary outcome of this study, ‘deterioration in functional capacity’ was defined as either an 142 
increase in MRC dyspnoea score of 1 point or more or a decrease in walking distance of 28 143 
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metres or more. Patients were classed as having ‘deteriorated functional capacity’ if they 144 
fulfilled either of these criteria. 145 
Comorbidities and baseline demographics were collected to assess for confounding factors 146 
between groups. Both surgical and anaesthetic technique were standardised.  147 
The sample size was calculated as per the primary objective of the initial study. No separate 148 
sample size calculation was carried out for this secondary endpoint. 149 
Statistical methods 150 
Statistical analyses were carried out using SPSS® (IBM Corp. Released 2013. IBM SPSS 151 
Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.). All variables were visually 152 
examined, and normality was tested using the Shapiro-Wilk test. Categorical data are 153 
presented as frequency (%) and continuous data are presented as mean (SD) if following a 154 
parametric distribution or median (IQR) if following a non-parametric distribution. Changes 155 
over time were assessed using the parametric repeated measures ANOVA or the non-156 
parametric Friedman’s test according to data distribution. Post-hoc pairwise comparisons 157 
were undertaken using a paired t-test or a Wilcoxon signed rank test. Independent samples t-158 
tests or Mann-Whitney U tests were used to compare independent groups. 159 
Association between continuous variables was assessed using the parametric Pearson’s 160 
correlation coefficient and the non-parametric Spearman’s rank order correlation coefficient 161 
according to data distribution. The predictive power of BNP to identify deteriorated functional 162 
capacity was assessed by examining the area under the Receiver Operating Characteristic 163 
curve (AUROC). Youden’s J statistic was used to identify the BNP value with the greatest 164 
predictive value. Patients with missing data for one or more parameters were included in the 165 
study; however, each individual comparison was made by complete case analysis. 166 
Statistical significance was defined as a p value<0.05. No adjustments were made for multiple 167 
comparisons. 168 
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Results 169 
Baseline data was collected pre-operatively on 27 patients. Patient demographic data is 170 
available in Table 1. All patients were alive at one-year follow up.  171 
Ninety-eight percent (132/135) of planned BNP samples were taken, with three missing at the 172 
two month time-point. Samples were missed at the two month time-point due to patients being 173 
unwell in other hospitals and therefore being unable to attend for follow-up. Patients returned 174 
90% (73/81) of MRC questionnaires and completed 85% (46/54) of walk tests. Two patients 175 
did not attend their 6MWT either pre-operatively or at the two month time-point, and so were 176 
excluded from 6MWT analysis.  177 
BNP 178 
BNP increased over time (p<0.01, Friedman’s) and was significantly elevated on POD1 and 179 
POD2 (p<0.02 for both, Wilcoxon Signed Rank Test) before returning to baseline two months 180 
post-operatively (Figure 1). There was no association between the number of lung segments 181 
resected and the increase in BNP from baseline to peak on POD2 (r=0.01 p=0.96, 182 
Spearman’s). 183 
BNP and Functional Capacity 184 
MRC Scale – subjective functional assessment 185 
Self-reported MRC dyspnoea scores are expressed in Figure 2. There was a significant 186 
difference in the distribution of MRC dyspnoea scores over time, with less patients reporting 187 
being “not troubled by breathlessness” and more patients reporting functional limitation at both 188 
post-operative time-points (p=0.03, Friedman’s). No patient reported improvement from 189 
baseline on this scale.  190 
BNP on POD1 was significantly associated with MRC scale results 2 months post-operatively 191 
(r=0.56, p<0.01, Spearman’s, Table 2). There was no association between pre-op BNP and 192 
post-op MRC scale (r=0.24, p=0.25). 193 
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Six Minute Walk Test – objective functional assessment  194 
Pre-operatively, the median six minute walk distance was 412 metres (360-486), which was 195 
unchanged 2 months post-operatively at 420 metres (363-474; p=0.64, Wilcoxon Signed Rank 196 
test). This comparison does not however reflect four patients who attended for 6MWT two 197 
months post-operatively, but declined to attempt the test due to severe dyspnoea. In total 11 198 
patients (44%) were either unable to walk as a result of severe dyspnoea, or walked at least 199 
28 metres less than baseline and were classified as having ‘deteriorated functional capacity’ 200 
for the purposes of analysis.  201 
Pre-op BNP was higher in patients with a reduced 6MWT distance (p=0.01, Mann-Whitney U). 202 
There was a significant negative association between high pre-op BNP levels and low two 203 
month post-op 6MWT distances (r=-0.43, p=0.05, Spearman’s). POD1 BNP was not 204 
associated with two month post-op 6MWT (r=-0.33, p=0.15, Table 2). 205 
Combined functional assessment - Composite of MRC scale and 6 Minute Walk Test  206 
Seventeen patients (68%) demonstrated deteriorated functional capacity two months post-207 
operatively. Within the group showing no functional limitation, there was no change in BNP 208 
over time (p=0.34, Friedman’s), however in the group demonstrating reduced functional 209 
capacity, BNP was significantly increased from baseline on POD1 and POD2 before reducing 210 
to baseline levels by 2 months post-operatively (p<0.01, Friedman’s test, Figure 3). BNP was 211 
higher in the group showing deteriorated functional capacity compared to the group exhibiting 212 
no change at all peri-operative time-points, including pre-operatively (p<0.01 for all, Mann 213 
Whitney U, Figure 3). There were no differences in baseline demographics (including baseline 214 
pulmonary function) between the two groups (Table 1). 215 
Pre-operative BNP was found to be predictive of a deterioration in functional capacity 2 216 
months post-operatively in this cohort, with an AUROC of 0.82 (p=0.01 95% CI: 0.65-0.99, 217 
Figure 4). A BNP of 46.5 pg/ml was found to have a sensitivity of 58% and a specificity of 218 
100% to predict deterioration in functional capacity 2 months following surgery. This gives 219 
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pre-op BNP a Positive Predictive Value (PPV) of 100% and a Negative Predictive Value 220 
(NPV) of 53%.  221 
Predicted Post-operative Lung Function 222 
Neither ppo-FEV1 nor ppo-DLCO were associated with MRC scale, 6MWT, or functional 223 
deterioration two months post operation (Table 3). There was no difference between ppo-224 
FEV1 or ppo-DLCO when comparing those who suffered functional deterioration with those 225 
who did not (p=0.37 and p=0.27 respectively, Independent Samples t-test, Figure 5). 226 
Discussion 227 
The main finding of this study is the observation that BNP is associated with patient reported 228 
dyspnoea and 6MWT distance following lung resection, and has predictive ability in identifying 229 
patients at risk of deterioration in functional capacity.  230 
As in previous studies, our study demonstrated significant deterioration in functional capacity 231 
following lung resection [3, 4]. In addition to significant changes in self-reported 232 
breathlessness, it is striking that at 2-months post-operatively, four of the patients presenting 233 
for post-operative follow-up declined to perform a 6MWT because they were “too breathless”. 234 
Our study also echoes the previously reported finding that deterioration in functional capacity 235 
was not well associated with changes in predicted post-operative lung function [5].  236 
The observation of poor association between changes in functional capacity and lung function, 237 
and the strong association between BNP, a quantitative biomarker of myocardial function and 238 
functional capacity adds weight to the hypothesis that cardiac impairment may contribute to 239 
limited functional capacity following lung resection. To date, there has been limited study of 240 
the influence of cardiac function in determining exercise and functional capacity following lung 241 
resection. Okada et al used volumetric pulmonary artery catheters to determine cardiac 242 
function in 10 patients undergoing lung resection and demonstrated reduced ejection fraction 243 
on exercise post-operatively [27]. Nezu et al performed cardiopulmonary exercise testing in 244 
82 patients undergoing lung resection demonstrating significantly reduced peak oxygen 245 
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consumption and maximal workload post-operatively[12]. In this group both maximum heart 246 
rate and oxygen-pulse were reduced and breathing reserve maintained post-operatively – a 247 
pattern of changes suggestive of cardiac limitation. 248 
Whilst previous studies have demonstrated increases in BNP post-operatively following lung 249 
resection, the observation that pre-operative BNP is predictive of post-operative exercise 250 
function two months later is a novel finding. It is plausible to suggest that BNP may have a 251 
future role in pre-operative risk stratification in this population allowing early identification of 252 
patients at increased risk of post-operative functional impairment. This could lead to several 253 
potential patient benefits: 254 
Firstly, this would serve to better inform the consent process. Recently revised guidelines on 255 
lung cancer surgery from the UK National Institute of Heath and Care Excellence (NICE) 256 
recommend that patients considered to be at increased risk of “dyspnoea and associated 257 
complications” should be offered surgical resection “if they accept the risks” [28]. Despite this, 258 
conventional risk assessment protocols advocated in this guideline or by the British Thoracic 259 
Society (BTS) [7], the American College of Chest Physicians (ACCP) [9] and the European 260 
Respiratory Society / European Society of Thoracic Surgeons (ERS/ESTS) [8] focus on 261 
prediction of post-operative dyspnoea by calculation of predicted post-operative lung function. 262 
Secondly, with greater understanding of the mechanisms of post-operative cardiac 263 
dysfunction, it may be possible to implement targeted strategies to reduce BNP and therefore 264 
risk pre-operatively. Alternatively, it may be possible to use BNP (alone or in concert with, for 265 
example, exercise testing) to stratify patients at increased risk of post-operative functional 266 
impairment to a peri-operative therapeutic pathway seeking to prevent post-operative cardiac 267 
dysfunction.  268 
Current ESA/ESC guidelines recommend considering using BNP to obtain prognostic 269 
information in high risk patients prior to non-cardiac surgery [21], yet the potential role of 270 
natriuretic peptides in aiding peri-operative decision making in patients undergoing lung 271 
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resection is unclear. There is no discussion of BNP in either BTS[7], ACCP[9] or ERS/ESTS[8]  272 
guidelines which specifically concern pre-operative assessment of patients undergoing lung 273 
resection. 274 
With BNP previously having been demonstrated to be predictive of the risk of early post-275 
operative complications [19] and long term survival following non-cardiac surgery [16],  and 276 
now in the current study to be predictive of longer term functional limitation, we suggest further 277 
work is required to explore the potential utility of BNP in the pre-operative assessment of 278 
patients undergoing lung resection. 279 
This study found that a BNP level of 46.5 pg/ml had the greatest sensitivity and specificity to 280 
predict deterioration in functional capacity in lung resection patients. This level of BNP 281 
however is lower than what is classically considered to be pathological; we believe this cut-off 282 
value allows identification of patients with sub-clinical cardiac dysfunction who are ‘at-risk’ of 283 
post-operative cardiac dysfunction, and that the further insult of lung resection is the 284 
precipitant that leads to functional deterioration. Previous work in other populations has 285 
demonstrated that similarly modest BNP values are predictive of left ventricular systolic and 286 
diastolic dysfunction [29, 30].  287 
Limitations 288 
As this study was an a-priori secondary endpoint of another study no power calculation was 289 
performed.  Sample size was relatively modest and this study may therefore have lacked the 290 
statistical power to detect meaningful changes between time-points and associations between 291 
variables. Similarly, the reported ‘positive findings’ would benefit from validation in a larger 292 
patient cohort. As discussed, and an inherent risk in all observational research of this type, 293 
there was a small amount of missing data in our study; a small proportion of this was due to 294 
patients being too ill to undergo scans or partake in walking tests, and this may have acted as 295 
a potential source of confounding. This is mitigated in part however by the patients who were 296 
unwilling to perform post-operative 6MWT due to breathlessness being classified in the 297 
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analysis as having suffered a significant deterioration in functional capacity. There was no 298 
quantification of the impact that pain had on patient dyspnoea. 299 
Additionally our participants were limited to a single tertiary cardiothoracic referral centre, and 300 
as such results may not be as applicable to other patient cohorts. Whilst the study population 301 
appeared to typify the ‘normal’ West of Scotland thoracic surgical population, these patients 302 
may bear a differing burden of comorbidity to those elsewhere. Finally, all of our patients 303 
received an open lung resection, and less invasive surgery such as VATS may yield differing 304 
results. 305 
Conclusion 306 
This study has demonstrated that preoperative BNP is as a predictor of functional deterioration 307 
following lung resection. Using both subjective and objective measures of functional capacity, 308 
pre-op BNP levels were shown to be predictive of post-operative functional deterioration, so 309 
strengthening their potential for use in peri-operative risk stratification in this population. 310 
FUNDING 311 
Funding for this project was provided by the Association for Cardiothoracic Anaesthesia and 312 
Critical Care Project Grant 2012.  313 
COMPETING INTERESTS 314 
None 315 
ETHICS APPROVAL 316 
West of Scotland research ethics committee (134/WS/0055)317 
16 
 
Figures and legends: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Change in BNP levels throughout the peri-operative period.  
Change over time assessed via Friedman’s test (p<0.01), pair-wise comparisons between timepoints assessed via Wilcoxon Signed Rank Test.  
  
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 - Change in MRC dyspnoea scores over time. 
Change over time p=0.03 (Friedman’s test).  
MRC Score (35): 1 - Not troubled by breathlessness except on strenuous exercise. 2 - Short of breath when hurrying on the level or walking up 
a slight hill. 3 - Walks slower than most people on the level, stops after a mile or so, or stops after 15 minutes walking at own pace. 4 – Stops for 
breath after walking about 100 yds or after a few minutes on level ground. 5 – Too breathless to leave the house, or breathless when 
undressing. 
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Figure 3 - Comparison of BNP levels between patients with deteriorated and unchanged functional capacity post-operatively.  
Change over time in patients showing functional deterioration – p<0.01 (Friedman’s). Change over time in patients showing no functional 
deterioration – p=0.03 (Friedman’s). Comparisons between groups carried out using Mann Whitney U Tests - † signifies p<0.01. 
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Figure 4 - ROC curve assessing ability of pre-operative BNP to predict Functional Deterioration 2 months post-operatively. 
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Figure 5 - Difference in BNP, predicted post-operative%FEV1, and predicted post-operative-DLCO between group showing functional 
deterioration, and group showing no functional deterioration.  
Differences measured using independent samples t-test or Mann-Whitney U test. 
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Tables  
Table 1 – Baseline Demographics.  
Differences assessed using independent samples t-tests, Mann-Whitney U tests, or Fisher’s 
exact test.   
 All Patients 
Functional 
Deterioration 
Unchanged 
Functional 
Capacity 
p value 
 n=27 n=17 n=8  
Age 65.5±9.6 68.8±7.6 59±11.1 0.34 
Male Gender 10(37%) 5(29%) 4(50%) 0.39 
BMI 26.08±3.89 25.61±3.96 26.19±3.39 0.73 
Smoking Status:     
- Current Smoker 13(48%) 9(53%) 4(50%) - 
- Ex-Smoker 12(44%) 7(41%) 3(38%) - 
- Never smoked 2(7%) 1(6%) 1(13%) - 
Pack Years 38±22 37±24 38±19 0.95 
FEV1 % Predicted 84±30 88±35 80±17 0.57 
PPO FEV1 (%) 68±21 72±24 63±14 0.37 
FEV1/FVC Ratio (%) 64±18 72(50-75) 
60 
(55-76) 
1 
DLCO (mmol/kPa/min) 5.16±1.74 4.67±1.62 5.98±1.75 0.08 
PPO DLCO (%) 51±12 49±13 55±10 0.27 
Thoracoscore 0.78(0.52 - 0.83) 0.66(0.51-0.93) 0.57(0.42-0.8) 0.32 
Pre-Op LVEF (%) 58(57-63) 60(54-65) 57(56-59) 0.53 
Past Medical History     
- History of Cancer 7(26%) 5(29%) 2(25%) 1 
- COPD 6(22%) 4(24%) 2(25%) 1 
- Hypertension 9(33%) 4(24%) 3(38%) 0.64 
- Heart Disease 6(22%) 3(18%) 2(25%) 1 
- Obesity 2(7%) 1(6%) 0(0%) 1 
- PVD 5(19%) 2(12%) 1(13%) 1 
Number of segments 
resected 
5 (3-5) 5 (3-5) 4 (3-5) 0.63 
Type of resection     
- Pneumonectomy 1(4%) 1(6%) 0(0%) - 
- Upper Lobectomy 16(59%) 11(65%) 4(50%) - 
- Lower Lobectomy 6(22%) 2(12%) 3(38%) - 
- Extended Upper 
Lobectomy 
1(4%) 1(6%) 1(13%) - 
- Extended Lower 
Lobectomy 
3(11%) 2(12%) 0(0%) - 
Pathology     
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- Primary Lung 
Cancer 
24(89%) 16(94%) 6(75%) - 
- Metastatic 
Malignancy 
1(4%) 1(6%) 0(0%) - 
- Benign Disease 2(7%) 0(0%) 2(25%) - 
Critical Care Stay (hours) 
47.23  
(29.21-53.47) 
47.15  
(28.7-51.25) 
53.13  
(29.5-71.45) 
0.37 
Hospital Stay (days) 8(7-11) 8(7-10.5) 9(7.25-19.5) 0.44 
 
BMI: Body Mass Index; FEV1: Forced Expiratory Volume in 1 second; PPO: Predicted Post 
Operative; FVC: Forced Vital Capacity; DLCO: Diffusion capacity of the lung for carbon 
monoxide; LVEF: Left Ventricular Ejection Fraction; COPD: Chronic Obstructive Pulmonary 
Disease; PVD: Peripheral Vascular Disease. 
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Table 2  
Association between BNP and measures of functional deterioration.  
Associations assessed via Pearson’s or Spearman’s correlation coefficients. Statistically 
significant results are highlighted in bold.  
BNP 
6MWT two months 
Post-Op 
MRC Scale two 
months Post-Op 
r p value r p value 
Pre-Op BNP -0.43 0.05 0.24 0.25 
POD1 BNP -0.33 0.15 0.57 0.01 
POD2 BNP -0.01 0.38 0.33 0.11 
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Table 3 
Association between predicted post-operative-lung function and measures of 
functional deterioration.  
Associations assessed via Pearson’s or Spearman’s correlation coefficients. PPO, predicted 
post-operative; FEV1, forced expiratory volume in 1 second; DLCO, diffusing capacity for 
carbon monoxide. 
 
6MWT two months 
Post-Op 
MRC Scale two 
months Post-Op 
Combined Functional 
Assessment two 
months Post-Op 
 r p value r p value r p value 
PPO FEV1 0.09 0.7 -0.18 0.38 -0.12 0.57 
PPO DLCO -0.03 0.9 -0.27 0.19 0.26 0.21 
 
25 
 
References 
[1] C. R. UK. Worldwide Cancer Statistics. 2015. 
[2] T. S. f. Cardiothoracic and S. i. G. B. Ireland. Second National Thoracic Surgery Activity & 
Outcomes Report 
 http://www.scts.org/_userfiles/resources/634558869917493937_Thoracic_2011_FINAL.pdf: The 
Society for Cardiothoracic Surgery in Great Britain & Ireland, 2011. 
[3] T. Win, A. M. Groves, A. J. Ritchie, F. C. Wells, F. Cafferty and C. M. Laroche. The effect of lung 
resection on pulmonary function and exercise capacity in lung cancer patients. Respir Care 
2007;52:720-6. 
[4] J. S. Wang, R. T. Abboud and L. M. Wang. Effect of lung resection on exercise capacity and on 
carbon monoxide diffusing capacity during exercise. Chest 2006;129:863-72. 
[5] C. Pelletier, L. Lapointe and P. LeBlanc. Effects of lung resection on pulmonary function and 
exercise capacity. Thorax 1990;45:497-502. 
[6] L. Sarna, L. Evangelista, D. Tashkin, G. Padilla, C. Holmes, M. L. Brecht et al. Impact of 
respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small 
cell lung cancer. Chest 2004;125:439-45. 
[7] E. Lim, D. Baldwin, M. Beckles, J. Duffy, J. Entwisle, C. Faivre-Finn et al. Guidelines on the 
radical management of patients with lung cancer. Thorax 2010;65 Suppl 3:iii1-27. 
[8] A. Brunelli, A. Charloux, C. T. Bolliger, G. Rocco, J. P. Sculier, G. Varela et al. ERS/ESTS clinical 
guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). 
Eur Respir J 2009;34:17-41. 
[9] A. Brunelli, A. W. Kim, K. I. Berger and D. J. Addrizzo-Harris. Physiologic evaluation of the 
patient with lung cancer being considered for resectional surgery. Diagnosis and management of lung 
cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. 
Chest 2013;143:e166S-e90S. 
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